People With Advanced AIDS Benefit From Dolutegravir Treatment

People With Advanced AIDS Benefit From Dolutegravir Treatment

MONTREAL — Patients with advanced HIV/AIDS infections had higher proportion of viral suppression with dolutegravir (Tivicay) treatment versus efavirenz (Sustiva) treatment, a researcher reported. At 48 weeks, 73.9% of the 92 patients assigned to a dolutegravir-based (DTG) regimen achieved viral suppression based on the 200 copies/ml assay versus 47.8% of the 92 patients assigned to …

People With Advanced AIDS Benefit From Dolutegravir Treatment Read More »